Walleye Capital’s Arcturus Therapeutics ARCT Stock Holding History

Walleye Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$130K	Buy	+19,323	New	+$152K	﹤0.01%	3742
2026 Q1	–	Sell	-1	Closed	-$6	–	4355
2025 Q4	$6	Buy	+1	New	+$11	﹤0.01%	4484
2025 Q1	–	Sell	-10,393	Closed	-$176K	–	4225
2024 Q4	$176K	Buy	+10,393	New	+$196K	﹤0.01%	3848
2024 Q3	–	Sell	-6,695	Closed	-$163K	–	5244
2024 Q2	$163K	Buy	+6,695	New	+$203K	﹤0.01%	4441
2022 Q3	–	Sell	-67,978	Closed	-$1.07M	–	3206
2022 Q2	$1.07M	Buy	+67,978	New	+$1.33M	0.03%	617
2021 Q2	–	Sell	-8,567	Closed	-$354K	–	1334
2021 Q1	$354K	Buy	+8,567	New	+$511K	0.02%	707

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Walleye Capital's ARCT Position: Q2 2026 in Review

Walleye Capital opened a new position in Arcturus Therapeutics (ARCT) in Q2 2026: 19,323 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #3742 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ARCT as recently as Q4 2025.

Walleye Capital first reported a position in ARCT in Q1 2021 and has held it in 6 quarters since. The position peaked at $1.07M in Q2 2022. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Walleye Capital held 19,323 shares of Arcturus Therapeutics worth $130K as of Q2 2026.
Arcturus Therapeutics was a new Walleye Capital position in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3742 holding.
Walleye Capital first reported a position in Arcturus Therapeutics in Q1 2021 and has held it in 6 quarters since.
Walleye Capital's Arcturus Therapeutics position peaked at $1.07M in Q2 2022.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.